A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD

OBJECTIVES: Three Phase 3 trials have demonstrated the efficacy and safety of SPN-812 in pediatric subjects with ADHD. Here, we report the results of a fourth trial. METHODS: Eligible adolescent subjects (N = 297) were randomized to SPN-812 (400- or 600-mg/day) or placebo. The primary efficacy endpo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Psychopharmacol Bull
Autores principales: Nasser, Azmi, Liranso, Tesfaye, Adewole, Toyin, Fry, Nicholas, Hull, Joseph T., Chowdhry, Fatima, Busse, Gregory D., Melyan, Zare, Cutler, Andrew J., Findling, Robert L., Schwabe, Stefan
Formato: Artigo
Lenguaje:Inglês
Publicado: MedWorks Media Global 2021
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8146561/
https://ncbi.nlm.nih.gov/pubmed/34092822
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares